Joint United Nations Programme on HIV/AIDS – Institutional Support 2013

Reporting Organization:UNAIDS - Joint United Nations Programme on HIV/AIDS
Total Budget ($CAD):$ 5,130,000
Timeframe: March 27, 2013 - June 30, 2014
Status: Completion
Contact Information: Unspecified

Partner & Funder Profiles

Reporting Organization

UNAIDS - Joint United Nations Programme on HIV/AIDS

Participating Organizations


Funders (Total Budget Contribution)

Return to top


Region - Total Budget Allocation

Europe - $ 1,282,500.00 (25.00%)

Sub-Saharan Africa - $ 1,128,600.00 (22.00%)

South America - $ 892,620.00 (17.40%)

Southeast Asia - $ 425,790.00 (8.30%)

Central America - $ 389,880.00 (7.60%)

South Asia - $ 348,840.00 (6.80%)

East Asia - $ 312,930.00 (6.10%)

Central Asia - $ 194,940.00 (3.80%)

North Africa - $ 153,900.00 (3.00%)

Return to top

Areas of Focus

Health - Total Budget Allocation

HIV (100 %)

Return to top


This grant represents Canada’s institutional support to the Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS uses these funds, along with other donors’ funding, to achieve its mandate. As the United Nation’s (UN) principal advocate for action on HIV/AIDS, UNAIDS works to prevent the transmission of HIV, provide treatment and care for people living with the disease, reduce the vulnerability of individuals and communities to HIV, and alleviate the epidemic’s impact worldwide. UNAIDS’ vision is to achieve the goal of ‘zero new infections, zero discrimination, and zero AIDS-related deaths’. UNAIDS brings together the resources of the UNAIDS Secretariat and 11 United Nations organizations for a coordinated and accountable response to the epidemic. UNAIDS is unique in that it was designed to work both at the country level, through other UN organizations, and globally, in the areas of global advocacy and technical guidance.

Return to top

Target Population

Gender and age: Adult women Adult men Adolescent females Adolescent males Children, girls Children, boys Under-5 children Newborns Older adults, women Older adults, men
Total Direct Population: Unspecified
Return to top



Return to top

Results & Indicators

Expected Results

The expected intermediate outcomes for this project include: (i) evidence-informed combination prevention policies and programmes for young people prioritized to specific localities and contexts; (ii) in low and concentrated epidemic settings, HIV incidence reduced among women of reproductive age, anti-retroviral drugs provided to women with HIV, and coverage of care and support for HIV-infected mothers, infants and partners scaled up; (iii) more people living with HIV diagnosed and receiving treatment for TB; (iv) burden of people suffering from tuberculosis among people living with HIV reduced; (v) stigma and discrimination reduced and access to justice increased for people living with HIV and for other key populations; (vi) gender-transformative HIV strategies are operationalized, as part of the UNAIDS Agenda for accelerated country action for women, girls, gender equality and HIV and; (vii) HIV strategies and programmes that integrate GBV and HIV with actions and resources that address and prevent both pandemics in an integrated manner.

Achieved Results

Results achieved as of December 2012 include: All 22 priority countries under the Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive accelerated their implementation programmes, with 17 countries finalizing their fully costed plans on the prevention of vertical transmission. Progress was made in keeping mothers alive: 64% of HIV positive women are now receiving anti-retroviral therapy, with a 24% decline among new HIV infections. Technical support in addressing HIV/tuberculosis co-infection has resulted in the roll-out of new rapid tests to 67 countries; in total, 119 countries tested more than 50% of tuberculosis patients for HIV. UNAIDS has also increased technical assistance for the implementation of Treatment 2.0 (which aims to catalyze the next phase of HIV treatment scale up through promoting innovation and efficiency gains) from 47% to 84% in high-impact countries.


  • None Selected
Return to top
Return to top

Associated Projects (If applicable)

Return to top